Cytokinetics CYTK Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's retained earnings?
- Cytokinetics (CYTK) reported retained earnings of -$3.69B in Q1 2026.
- How has Cytokinetics's retained earnings changed year-over-year?
- Cytokinetics's retained earnings decreased by 29.0% year-over-year, from -$2.86B to -$3.69B.
- What is the long-term trend for Cytokinetics's retained earnings?
- Over 5 years (2020 to 2025), Cytokinetics's retained earnings has grown at a 28.6% compound annual growth rate (CAGR), from -$992.31M to -$3.49B.
- What does retained earnings mean?
- The total profit or loss the company has generated over its entire history.
- How do you interpret retained earnings?
- A negative balance is standard for pre-commercial biotechs; a shift toward positive indicates the company has reached profitability.
- How does retained earnings compare across companies?
- Deeply negative for clinical-stage firms; positive for mature, commercial-stage pharmaceutical companies.